



Special Coagulation

State-of-the-Art Coag Department

Urgent coagulation needs? We're here for you when every minute counts! Our advanced laboratory department offers premium testing and serves as a reference lab for other hospitals in the area.

Special Coagulation Client Test Menu

Thrombotic / Clotting Disorders

ACQUIRED THROMBOTIC PROFILE*
ADAMTS-13 REFLEX TO INHIBITOR
ANTIPHOSPHOLIPID LUPUS SCREEN*
APC-RESISTANCE
ANTI-THROMBIN III (AT3) ACTIVITY
ANTI-THROMBIN III (AT3) ANTIGEN
COMPREHENSIVE HYPERCOAG PROFILE*
DIC PROFILE*
FACTOR V LEIDEN PROFILE*
HYPERCOAG PROFILE*
HYPERCOAG PROFILE WITH COUMADIN*
HYPERCOAG PROFILE WITHOUT COUMADIN*
LUPUS ANTICOAGULANT ASSAY
LUPUS ANTICOAGULANT WITH PHOSPHOLIPIDS*
FUNCTIONAL PROTEIN C ACTIVITY
FUNCTIONAL PROTEIN S ACTIVITY
FUNCTIONAL PROTEIN C ACTIVITY AND ANTIGEN
FUNCTIONAL PROTEIN C AND S ACTIVITY WITH REFLEX PLASMINOGEN
PROTEIN C ACTIVITY
PROTEIN C ANTIGEN
PROTEIN S FREE
PROTEIN S FREE AND TOTAL
PROTEIN S PANEL*
PROTEIN S TOTAL ANTIGEN
THROMBIN TIME

Phospholipid Antibody Detection

CARDIOLIPIN ABS IGG, IGM, IGA
PHOSPHATIDYLSERINE ABS IGG, IGM, IGA
ANTIPROTHROMBIN ANTIBODY IGG
BETA-2 GLYCOPROTEIN ABS IGG, IGM, IGA
PHOSPHOLIPID ANTIBODY PROFILE

HIT Testing

HIPA (HEPARIN INDUCED PLATELET ANTIBODY)
--

Bleeding Disorders

BLEEDING PROFILE
FACTOR II (2) ACTIVITY
FACTOR V (5) ACTIVITY
FACTOR VII (7) ACTIVITY
FACTOR VIII (8) ACTIVITY
FACTOR VIII (8) ANTIGEN
FACTOR VIII (8) CHROMOGENIC
FACTOR IX (9) ACTIVITY
FACTOR X (10) ACTIVITY
FACTOR XI (11) ACTIVITY
FACTOR XII (12) ACTIVITY
FACTOR XIII (13) ANTIGEN
VON WILLEBRAND'S SCREEN*

Anticoagulant Medication Monitoring

ANTI FACTOR XA UFH
ANTI FACTOR XA LMWH
APIXABAN (ELIQUIS) LEVEL
RIVAROXABAN (XARELTO) LEVEL

Circulating Inhibitors

CIRCULATING INHIBITOR
MIXING STUDY
FACTOR II (2) INHIBITOR PROFILE*
FACTOR V (5) INHIBITOR PROFILE*
FACTOR VII (7) INHIBITOR PROFILE*
FACTOR VIII (8) INHIBITOR PROFILE*
FACTOR IX (9) INHIBITOR PROFILE*
FACTOR X (10) INHIBITOR PROFILE*
FACTOR XI (11) INHIBITOR PROFILE*
FACTOR XII (12) INHIBITOR PROFILE*
NIJMEGEN FACTOR VIII (8) INHIBITOR PROFILE*
NIJMEGEN FACTOR IX (9) INHIBITOR PROFILE*

Effective April 2024